Frontage’s Bioanalytical team partnered with Eisai (ESALY) / Biogen (BIIB) to support the PK and PD biomarker bioanalysis of lecanemab in their investigational global phase 3 study in US and China. Recently Eisai/Biogen publicly shared the favorable results of the lecanemab Clarity AD study which Eisai presented on November 29, 2022, at the Clinical Trials on Alzheimer’s Disease Congress, and published the findings in NEJM. The Frontage team developed and validated the LC-MS-based PK method back in 2010 and provided bioanalytical support to this program from clinical Phase 1 to the late phase trial. Frontage’s scientific team also provided biomarker analysis for this Phase 3 study and met the very aggressive timelines of data lock. "Here at Frontage, we also celebrated this news because it’s a powerful reminder of the reason we are in this field-to work towards combating disease and positively improving the lives of others. We are very proud to have worked closely with our Eisai partners to support the bioanalysis of lecanemab (BAN2401) in this large global phase 3 study. We are extremely proud to be a part of the team and hope to contribute to the unmet medical needs of patients with Alzheimer’s disease," announces John Lin, Frontage’s EVP and Global Head, Bioanalytical and Biologics Services.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ESALY:
- Anavex price target raised to $80 from $40 at JonesTrading
- Mizuho healthcare analysts to hold an analyst/industry conference call
- Mizuho says Biogen not mentioned in 90 minute lecanemab presentation
- Biogen price target raised to $350 from $325 at Jefferies
- Biogen and Eisai’s Alzheimer’s Drug May Pose Serious Risks, Say Researchers
